Hypertrophic Cardiomyopathy Hcm clinical trials

Explore recruiting hypertrophic cardiomyopathy hcm clinical trials.

Recruiting hypertrophic cardiomyopathy hcm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypertrophic Cardiomyopathy Hcm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)

Italy, Romania, France, Belgium, Sweden, Portugal +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Follow-Up, Open Label, Research Evaluation of Sustained Treatment with Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

Netherlands, Poland, Portugal, France, Denmark, Germany +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

Spain, Netherlands, Denmark, France, Belgium, Czechia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

Poland

Therapeutic use (Phase IV) EU CTIS Study details

Hypertrophic Cardiomyopathy Hcm trials by city

Hypertrophic Cardiomyopathy Hcm in Toronto Hypertrophic Cardiomyopathy Hcm in Vancouver Hypertrophic Cardiomyopathy Hcm in Montreal Hypertrophic Cardiomyopathy Hcm in Calgary Hypertrophic Cardiomyopathy Hcm in Edmonton Hypertrophic Cardiomyopathy Hcm in Ottawa Hypertrophic Cardiomyopathy Hcm in Winnipeg Hypertrophic Cardiomyopathy Hcm in Quebec City Hypertrophic Cardiomyopathy Hcm in Hamilton Hypertrophic Cardiomyopathy Hcm in Kitchener Hypertrophic Cardiomyopathy Hcm in London Hypertrophic Cardiomyopathy Hcm in Halifax Hypertrophic Cardiomyopathy Hcm in New York Hypertrophic Cardiomyopathy Hcm in Los Angeles Hypertrophic Cardiomyopathy Hcm in Chicago Hypertrophic Cardiomyopathy Hcm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease